Annexon Offers High-Risk, High-Reward Play in Complement-Mediated Diseases

Annexon offers a high-risk, high-reward investment opportunity for a new approach to complement-mediated diseases. While systemic complement-mediated diseases are rare, complement overactivation plays a significant role in other hard-to-treat diseases with serious quality of life implications. Annexon's approach aims to address these diseases, which are often difficult to treat and have significant quality of life implications.